BCL2L1 and B-cell chronic lymphocytic leukemia: Navitoclax showed good effect on chronic lymphocytic leukemia (CLL) and small-cell lung cancer in clinical trials, however, it showed dose-limiting thrombocytopenia because of the role of Bcl-XL in platelet production25,26.